{"filing":{"accession_number":"0001493152-26-029374","cik":"0001855485","ticker":"CLDWW","company_name":"Calidi Biotherapeutics, Inc.","form":"8-K","filing_date":"2026-06-18","report_date":null,"primary_document":"form8-k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1855485/000149315226029374/form8-k.htm"},"events":[{"id":11966,"run_id":10529,"accession_number":"0001493152-26-029374","anchor_item_number":null,"event_type":"shareholder_vote_results","event_domain":"governance","is_material":true,"confidence":0.95,"summary":"The filing discloses results from Calidi Biotherapeutics' 2026 Annual Meeting of Stockholders held on June 12, 2026, under Item 5.07. Four proposals were voted on and approved: election of Scott Leftwich as Class III Director, ratification of CBIZ CPAs P.C. as auditor, approval of a reverse stock split (1-for-2 to 1-for-16 ratio at board discretion), and amendment to the 2023 Equity Incentive Plan to increase authorized shares from 282,815 to 1,950,000. The reverse stock split and equity plan amendment are material corporate actions affecting share structure and equity compensation capacity.","company_name":"Calidi Biotherapeutics, Inc.","ticker":"CLDWW","filing_date":"2026-06-18","form":"8-K","submitted_at":null,"items":null}],"classifications":[{"id":8690,"accession_number":"0001493152-26-029374","item_number":null,"item_title":null,"event_type":"shareholder_vote_results","event_domain":"governance","is_material":true,"confidence":0.95,"reasoning":"The filing discloses results from Calidi Biotherapeutics' 2026 Annual Meeting of Stockholders held on June 12, 2026, under Item 5.07. Four proposals were voted on and approved: election of Scott Leftwich as Class III Director, ratification of CBIZ CPAs P.C. as auditor, approval of a reverse stock split (1-for-2 to 1-for-16 ratio at board discretion), and amendment to the 2023 Equity Incentive Plan to increase authorized shares from 282,815 to 1,950,000. The reverse stock split and equity plan amendment are material corporate actions affecting share structure and equity compensation capacity.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-18T21:03:14.356110+00:00","company_name":"Calidi Biotherapeutics, Inc.","ticker":"CLDWW","filing_date":"2026-06-18"}]}